Quizzes

True or False: According to findings from a real-world data comparison, mosunetuzumab monotherapy demonstrated promising outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic...

What was the key finding from a dose-expansion study assessing a combination of pembrolizumab plus vorinostat among patients with R/R classical Hodgkin lymphoma, particularly among those refractory to PD-1 blockade?

Did belzutifan improve the time to deterioration among patients with advanced clear cell renal cell carcinoma when compared with everolimus?

Based on results from the phase 3 FLAURA 2 trial the US FDA has approved osimertinib plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon...

Study results indicated that the addition of capivasertib to fulvestrant improved PFS from 3.6 months to ____ months.

True or False: Aspacytarabine demonstrated efficacy and safety among patients with acute myeloid leukemia who were young and fit for intensive chemotherapy, according to a phase 2b trial.

True or False: Momelotinib displayed clinically meaningful symptom benefits among patients with myelofibrosis, according to a study that demonstrated insight into the appropriateness of the symptom change threshold used in the phase 3...

The addition of parsaclisib to stable-dose ruxolitinib treatment ___ splenomegaly and ___ symptom scores among patients with primary or secondary myelofibrosis who did not have optimal responses to ruxolitinib alone, according to findings...